Skip to main content
Erschienen in: BMC Cancer 1/2019

Open Access 01.12.2019 | Research article

The effect of diabetes on the risk of endometrial Cancer: an updated a systematic review and meta-analysis

verfasst von: Lotfolah Saed, Fatemeh Varse, Hamid Reza Baradaran, Yousef Moradi, Sorour Khateri, Emilie Friberg, Zaher Khazaei, Saeedeh Gharahjeh, Shahrzad Tehrani, Amir-Babak Sioofy-Khojine, Zahra Najmi

Erschienen in: BMC Cancer | Ausgabe 1/2019

Abstract

Background

Previous studies conducted on the association between diabetes and the risk of endometrial cancer have reported controversial results that have raised a variety of questions about the association between diabetes and the incidence of this cancer. Thus, the aim of this systematic review and meta-analysis was to more precisely estimate the effect of diabetes on the risk of endometrial cancer incidence.

Methods

All original articles were searched in international databases, including Medline (PubMed), Web of sciences, Scopus, EMBASE, and CINHAL. Search was done from January 1990 to January 2018 without language limitations. Also, logarithm and standard error logarithm relative risk (RR) were used for meta-analysis.

Results

A total of 22 cohort and case-control studies were included in this meta-analysis, of which 14 showed statistically significant associations between diabetes and risk of endometrial cancer. Diabetes was associated with increased risk of endometrial cancer (RR = 1.72, 95% CI 1.48–2.01). The summary of RR for all 9 cohort studies was 1.56 (95% CI 1.21–2.01), and it was 1.85 (95% CI 1.53–2.23) for 13 case control studies. The summary of RR in hospital-based studies was higher than other studies. Thirteen of the primary studies-controlled BMI as a confounding variable, and the combined risk of their results was 1.62 (95% CI 1.34–1.97).

Conclusions

Diabetes seems to increases the risk of endometrial cancer in women, and this finding can be useful in developing endometrial cancer prevention plans for women having diabetes.
Hinweise

Publisher’s Note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.
Abkürzungen
BMI
Body weight index
CI
Confidence interval
CINAHL
Cumulative index to nursing and allied health literature
EMBASE
Excerpta medica dataBASE
HR
Hazard ratio
IDDM
Insulin-dependent diabetes mellitus
MOOSE
Meta-Analyses of Observational Studies in Epidemiology
NIDDM
Non-insulin-dependent diabetes mellitus
OR
Odds ratio
RR
Risk ratio or relative risk
STROBE
Strengthening the Reporting of Observationally Studies in Epidemiology

Background

A recent study conducted by Lortet-Tieulent, J and colleague show that endometrial cancer is the sixth most commonly occurring cancer in women and the 15th most commonly occurring cancer overall. There were over 380,000 new cases in 2018 [1]. Also, about 142,000 women are diagnosed with endometrial cancer annually worldwide, and about 42,000 women lose their life due to endometrial cancer. The usual curve of endometrial cancer indicates that most cases are diagnosed after menopause, and the highest incidence rate is around the seventh decade of life [2]. The disease is more than 10 times common in North America and Europe than in less developed countries [3]. The incidence and the mortality rate of endometrial cancer increased during 2006 and 2010 [4]. Estrogens, both internal and external, play an important role in increasing endometrial cancer [5]. Several studies have shown that the risk of endometrial cancer increases with older age, early menstruation, late menopause, obesity, family history of endometrial cancer (especially among close relatives), exposure to radiation, infertility (especially due to polycystic ovarian syndrome), and long-term use of estrogens for hormone therapy [47]. Estrogens, both internal and external, play an important role in increasing endometrial cancer. Multiple studies have claimed a positive association between diabetes and incidence of endometrial cancer with several biological mechanisms [8]. However, a previous systematic review and meta-analysis was performing by Friberg and colleges [8] but growing several publications afterwards and also considering new variables in adjusted models, we felt to design an updated systematic review and meta-analysis in order to show any posible relationship between diabetes and endometrial cancer.

Methods

This systematic review was performed according to the Meta-Analyses of Observational Studies in Epidemiology (MOOSE) and Strengthening the Reporting of Observationally Studies in Epidemiology (STROBE) guidelines for reviews of analytical observational studies (case-control and cohort) [2, 9, 10].

Search strategy

All original published articles were searched in international databases, including Medline (PubMed), Web of sciences, Scopus, EMBASE, and CINHAL. Search was done from January 1990 to January 2018 without language limitations. The keywords were Diabetes, Diabetes Mellitus (type 1 and 2), Insulin Dependent, IDDM, NIDDM, Noninsulin Dependent, Endometrial Stromal Tumors, Endometrial Neoplasms, and Endometrial. The selected studies were limited to observational studies on humans.
The primary search results were reviewed, and some of the articles were eliminated after reviewing their title and an abstract. Inclusion and exclusion criteria were set by 2 researchers separately (YM, FV) (Fig. 1).

Eligibility criteria

A published study had to meet the following inclusion criteria:
(1) original article, (2) case-control or cohort study, (3) human population, (4) diabetes and patients with diabetes as the main independent variable, and (5) endometrial cancer as the dependent variable. Case reports, reviews, animal studies, and case control or cohort studies with crude estimates about the effect of diabetes on the risk of endometrial cancer were removed from the tabulation. The authors resolved all disputes during the collection, compilation, and analysis of data.

Data extraction

Two researchers evaluated all included articles independently. They assessed the disagreement, if any, and in case an agreement was not reached, a third author (LS) evaluated the study. Two independent matched reviewers extracted the data according to a uniform Excel sheet. Then, a structured checklist was used to extract the following information: (1) author, (2) year of publication, (3) type of study, (4) country, (5) study population, (6) age of women, (7) sample size, (8) type of diabetes, (9) measurement, and (10) adjusted variables of association.

Statistical analysis

In the meta-analysis, 3 measures of association were used: (1) odds ratio (case-control and population-based case-control studies), (2) relative risk (cohort and population cohort studies), and (3) hazard ratio (cohort and population-based cohort studies). As the frequency of endometrial cancer was relatively low, the odds ratio in the case-control and population based case-control studies and the risk ratio in the cohort and population-based cohort studies yielded similar estimates of relative risk (RR) [11].
Logarithm and standard error logarithm relative risk (RR) were used for the meta-analysis. DerSimonian and Laird method was used to compute the pooled estimate of relative risk (RR) with confidence interval (CI 95%) using random models [12]. Because the test for heterogeneity was statistically significant in some analyses, the random effects models were used to estimate RR. In this study, w Cochran’s Q test and I2 statistic were used to evaluate statistical heterogeneity between studies [13]. In addition, a meta-regression and subgroup analysis was performed to assess the source of heterogeneity between studies. Moreover, publication bias was assessed by funnel plot and Egger and Begg’s test [14, 15]. Statistical analysis was performed using STATA 14.0 (Stata Corp, College Station, TX, USA), and statistical significance was set at p < 0.05.

Results

Study characteristics

A total of 22 studies were included in this meta-analysis (Fig. 1), of which 9 were cohort and population cohort studies [46, 1621] (Table 1) and 13 were case-control and population case-control studies [2234] (Table 2). Also, 12 studies were conducted in the USA [4, 5, 16, 19, 20, 22, 27, 2932, 34], 4 in Sweden [17, 18, 21, 33], 2 in Italy [25, 26], 1 in Canada [23], 1 in Norway [6], 1 in Mexico [28], and 1 in Japan [24]. The case-control and population case-control studies (n = 13) comprised 22,392 controls and 7698 endometrial cancer cases.
Table 1
The Main Characteristics of Cohort and Population-based Cohort Studies on Diabetes and Endometrial Cancer Risk
Authors
Year
Type of study
Country
Study population
Age
Sample size
Type of diabetes
Measurement of association
Controlled variables
Al Hilli. M, et al. [16]
2015
Cohort
USA
database for the records of all patients who underwent primary surgical intervention for EC, from January 1, 1999, through December 31, 2008.
All age
1303
Diabetes
HR: 1.01; % 95 CI (0.72,1.42)
Age, BMI
Friberg. E, et al. [17]
2007
Cohort
Sweden
Exposed group: 1628 women with self-reported DM or DM from national inpatient register
Comparison group: 35145 women without self-reported DM or DM from national inpatient register
50–83
36,773
Diabetes
RR: 1.94; % 95 CI(1.23,3.08)
Age, BMI, total physical activity
Anderson. K, et al.[5]
2001
Cohort
USA
Exposed group: 1325 women with self-reported DM
Comparison group: 23150 women without self-reported DM
55–69
24,475
Diabetes
RR: 1.43; % 95 CI(0.98,2.09)
Age, BMI, BMI2, WHR, ovulatory span, gravidity, PMH, menstrual irregularities, hypertension
Lindemann. K, et al. [6]
2008
Cohort
Norway
Norwegian women during 15.7 years of follow-up.
All age
36,761
Diabetes
RR: 3.84 (% 95 CI: 1.92,5.11)
Age
Folsom. A, et al. [20]
2004
Cohort
USA
Exposed group: 42 women with self-reported DM and an endometrial cancer diagnosis
Comparison group: 373 women with self-reported DM and an endometrial cancer diagnosis
55–69
415
Diabetes
RR: 2.38 (% 95 CI: 1.05,5.37)
Age, extent of endometrial cancer at diagnosis
Luo. J, et al. [4]
2014
Cohort
USA
Women’s Health Initiative
50–79
88,107
Diabetes
HR: 1.16 (% 95 CI: 0.90,1.48)
Age, BMI
Terry. P, et al. [21]
1999
Cohort
Sweden
Exposed group: 142 women with self-reported DM
Comparison group: 10012 women without self-reported DM
42–81
10,154
Diabetes
RR: 1.60 (% 95 CI: 0.20,11.30)
Age, physical activity, weight, parity
Coughlin. S, et al. [19]
2004
Cohort
USA
Exposed group: 33 women with self-reported DM
Comparison group: 448 women without self-reported DM
> 30
481
Diabetes
RR: 1.33 (% 95 CI: 0.92,1.90)
Age, race, education, BMI, smoking, alcohol, red meat, citrus fruit and juice, vegetables, physical activity, PMH, parity, age at menarche, age at first live birth, menopausal status, OC
esLambe. M, et al. [18]
2011
Cohort
Sweden
individuals that took part in routine health checkups and primary care patients referred for laboratory testing
All age
230,737
Diabetes
HR: 1.46(% 95 CI 1.09,1.96
Age
Table 2
The Main Characteristics of Case-Control and Population Case-Control Studies on Diabetes and Endometrial Cancer Risk
Authors
Year
Country
Control subjects (selection methods)
Age
Sample size
Type of diabetes
Measurement of association
Controlled variables
Weiderpass. E, et al. [33]
2000
Sweden
Control women were randomly selected from a continuously updated population register that includes all residents.
50–74
Case(709)
Diabetes
OR: 1.7 (% 95 CI: 1.2,2.3)
Age, age at menarche, parity, age at last birth, age at menopause, smoking, OC, PMH, BMI
Control(3368)
T(4077)
Shoff. SM, et al. [30]
1998
USA
Community controls were selected randomly from lists
40–79
Case(723)
Diabetes
OR: 1.10 (% 95 CI: 0.66,1.86)
Age, BMI, smoking, PMH, parity, education
Control(2291)
T(3014)
Lucenteforte. E, et al. [25]
2007
Italy
Controls women admitted to the same network of hospitals
18–79
Case(777)
Diabetes
OR: 2.0 (% 95 CI: 1.4,2.9)
Age, year of interview, study center, education, parity, menopausal status, OC and HRT use
Control(1550)
T(2327)
Friedenreich. CM, et al. [23]
2011
Canada
Controls selected from the Alberta Cancer Registry
30–79
Case(515)
Diabetes
OR: 1.31(95% CI: 1.03,1.67)
Age, parity, education, age at menarche, hormone therapy, age at menopause, history of Type 2 diabetes, hormone contraception, oral and non-oral hormone use, history of angina, history of stroke, history of thrombosis, smoking and alcohol consumption
Control(962)
T(1447)
Saltzman. BS, et al. [29]
2007
USA
Controls selected from Women’s Contraceptive and Reproductive Experiences (CARE) breast cancer study
45–74
Case(1303)
Diabetes
OR: 1.7(% 95 (CI: 1.2, 2.3)
Country, age, reference year, body mass index, and menopausal hormone use
Control(1779)
T(3082)
Parazzini. F, et al. [26]
1999
Italy
Controls selected from same network of hospitals where cases had been identified.
28–74
Case(752)
Diabetes
OR: 3.1 (% 95 CI: 2.3,4.2)
Age, calendar year, education, BMI, parity, OC, PMH, age at menopause, hypertension, smoking
Control(2606)
T(3358)
Wartko. PD, et al. [32]
2017
USA
Control were randomly selected from all other women with delivery records from 1987 to 2013.
All age
Case(593)
Diabetes
OR: 1.80 (% 95 CI: 1.22,2.65)
Race/ethnicity, year of delivery, maternal age at delivery, and body mass index
Control(5743)
T(6336)
Soliman. PT, et al. [31]
2006
USA
Controls patient samples were obtained through a low-risk cancer screening program
All age
Case(117)
Diabetes
OR: 1.87 (%95, CI: 0.77,4.54)
Lower serum adiponectin level, age, BMI, and hypertension
Control(238)
T(355)
Rubin. GL, et al.[27]
1990
USA
population controls, matched for place of residence and age
20–54
Case(196)
Diabetes
OR: 1.80 (%95, CI: 0.90,3.60)
Age
Control(986)
T(1182)
Brinton. L A, et al. [22]
1992
USA
Population controls random digit dialing for younger controls and health care financing administration for older controls, older controls were matched on age, race and zip code
20–74
Case(405)
Diabetes
OR: 1.95 (%95, CI: 1.10,3.60)
Age, education, number of births, weight, OC, PMH
Control(279)
T(684)
Inoue. M, et al. [24]
1994
Japan
hospital control who underwent hysterectomy due to benign gynecological tumors, matched on year of admittance to hospital and age
22–79
Case(143)
Diabetes
OR: 7.75 (%95, CI: 1.52,40.0)
Age, parity, cancer history, hypertension, obesity
Control(143)
T(286)
Weiss. J M, et al. [34]
2006
USA
Population that matched on age
45–75
Case(1281)
Diabetes
OR: 1.58 (%95, CI: 1.20,2.07)
Age, PMH, BMI, county, referent year, tumors aggressiveness
Control(1779)
T(3060)
Salazar. M E, et al.[28]
2000
Mexico
Hospital, from primary health center i.e. outpatient, matched on age
NA
Case(85)
Diabetes
OR: 3.60 (%95, CI: 1.70,7.40)
Age, an ovulatory index, smoking, physical activity, menopausal status, hypertension, BMI
Control(668)
T(753)
The overall and individual results of 22 cohort and case-control studies are shown in Fig. 2. Of the 22 studies, 14 showed statistically significant associations between diabetes and risk of endometrial cancer. Occurrence of diabetes had an association with increased risk of endometrial cancer (RR = 1.72, 95% CI 1.48–2.01) (Figs. 2 and 3). The results demonstrated heterogeneity of the studies (I2 = 66.7%; P < 0.0001). However, no evidence of publication bias was found based on the results of the Egger’s test (Egger’s test: t = 1.90, P = 0.072, 95% CI: − 0.04-0.91).

Subgroup analysis

The subgroup analysis was conducted based on the study design, and variables adjustment (Table 3). Individual study results and the overall summary results for 8 cohorts and 7 population-based, 2 hospital-based, and 5 case-control studies investigating the effect of diabetes on the risk of endometrial cancer in women are shown in Table 3. The results indicated that the summary of RR for all the 8 cohort studies combined was 1.52 (95% CI 1.16–2.00), and heterogeneity among these studies was significant (Q = 3.03, I2 = 70.7%; P = 0.001). The summary of RR for all the 7 population-based case–control studies was 1.55 (95% CI 1.37–1.75), however, heterogeneity among these studies was not significant (Q = 6.88, I2 = 0.0%; P = 0.461). In addition, the summary of RR for all the 5 case-control studies was 2.31 (95% CI 1.81–2.96), but heterogeneity was not significant (Q = 6.69, I2 = 22.7%; P = 0.270). Also, the summary of RR was higher in hospital-based studies than in other studies [RR = 4.10 (CI 95% 2.09–8.01), heterogeneity was Q = 4.12, I2 = 0.0%, P = 0.402]. According to the results in Table 3, the summary of RR in hospital-based studies was higher than in other studies. Also, 13 of the primary studies-controlled BMI as a confounding variable, and the combined risk of their results was 1.62 (95% CI 1.34–1.97, test for heterogeneity: Q = 4.14, I2 = 71.0%, P = 0.0001). However, 4 of the primary studies-controlled weight as a confounding variable, and the combined risk of their results was 2.45 (95% CI 1.14–5.26, test for heterogeneity: Q = 2.53, I2 = 21.0%, P = 0.021).
Table 3
Summary Relative Risk (RR) Estimates [95% confidence intervals (CIs)] for Case–Control and Cohort Studies Conducted on the Association Between Diabetes and Endometrial Cancer Incidence by Study Design, Continent, and Age
Subgroup
Number of studies
Summery Relative Risk (95% CI)
Between studies
Between subgroups
I2
P heterogeneity
Q
Q
P heterogeneity
Study design
 Cohort
8
1.52 (1.16–2.00)
70.7%
0.001
3.03
5.79
0.001a
 Case-Control
5
2.31 (1.81–2.96)
22.7%
0.270
6.69
  
 Population-based
7
1.55 (1.37–1.75)
0.0%
0.461
6.88
4.95
0.034b
 Hospital-based
2
4.10 (2.09–8.01)
0.0%
0.402
4.12
 Adjustment
3
1.88 (1.48–2.38)
81.9%
0.004
5.21
8.78
0.045
 Age
13
1.62 (1.34–1.97)
71.0%
0.0001
4.14
 BMI
3
2.45 (1.14–5.26)
21.0%
0.021
2.53
 Weight
4
1.89 (1.22–2.94)
50.6%
0.108
6.08
 Physical Activity
     
Largely diabetes mellitus
All statistical tests were 2-sided
aTest for heterogeneity between case-control and cohort studies
bTest for heterogeneity between population-based and hospital-based case-control studies
Also, the summary of RR of primary studies, whose results were adjusted based on BMI showed a less value compared to summary of RR of primary studies, whose results were adjusted based on weight control (1.62; 95% CI 1.34–1.97 Vs 2.45; 95% CI 1.14–5.26). Physical activity was adjusted in 4 primary studies, and the summary of RR based on controlling this variable was 1.89 (95% CI 1.22–2.94, test for heterogeneity Q = 6.08, I2 = 50.6%, P = 0.108) (Table 3).

Discussion

The results of this meta-analysis showed that women with diabetes had a 72% increased risk of endometrial cancer compared to those without diabetes as supports the previous meta-analysis conducted by E. Friberg et al. (31) in 2007. Also, other studies have shown that diabetes increased the risk of endometrial cancer, which is in line with the results of the present study [5, 6, 16, 23, 26, 32, 35].
Based on subgroup analysis, the risk of endometrial cancer in case-control studies was higher than in cohort studies, and a higher risk was observed in hospital-based studies compared to population-based studies. [3638].
Since the results of case-control and hospital-based studies are more prone to be affected by confounders therefore the calculated risk might be over-estimated. [3941].
In our meta-analysis, heterogeneity was 66.7% for overall risk, which was reduced by subgroup analysis based on type of study, so the heterogeneity for each group for RR in cohort studies, case-control studies, population-based studies, and hospital-based studies were 70.7, 22.7, 0, and 0%, respectively. Furthermore, in this study, it was found that the levels of heterogeneity in physical activity, weight, and BMI had decreased remarkably. It can be concluded from the analysis that the causes of heterogeneity in determining the overall risk of endometrial cancer in women with diabetes in the present meta-analysis were type of study, adjusted co-variables and geographical area (Fig. 2).
Obesity, which is one of the most important factors in diabetes, can cause hormonal imbalances in the body, and this in turn predisposes a person to endometrial cancer [26, 4244]. One of the risk factors for type 2 diabetes is obesity, which is also a major risk factor for endometrial cancer. Although the precise mechanisms and pathways are uncertain, it could be hypothesized that endometrial carcinogenesis is that exposure of the endometrium to excess estrogen unopposed by progesterone increases the mitogen activity of endometrial cells [45, 46]. In this meta-analysis the summary of RR of primary studies, whose results were adjusted based on BMI showed a less value compared to summary of RR of primary studies, whose results were adjusted based on weight control. In women with obesity the levels of estradiol and estrogen are higher than women with normal weight, [47, 48], and this could be one the possible reason for the increase risk of endometrial cancer because of obesity [48]. However, results of several studies showed that other factors, such as higher insulin levels and growth factors, may also increase the risk of endometrial cancer in women with obesity [49, 50]. Moreover, long-term insulin therapy may also be responsible for increased risk of endometrial cancer in women with diabetes (31).
In this study, the authors performed subgroup analysis based on type of primary studies, geographical area, and adjusted covariate. However, we could not perform subgroup analysis based on type of diabetes (type 1 and type 2) because the early studies did not specify or separate the types of diabetes. Diabetes is a chronic disease, whose diagnosis may not be accurate and specific, in which case it would lead to classification bias (non-differential misclassification). Therefore, the overall results obtained from primary studies should be interpreted with caution.
However most of included case-control and cohort studies in this meta-analysis controlled the variables of obesity and sedentariness but it is of utmost importance to consider the effect of confounding variables (sedentariness, hormonal disorders, and obesity) on determining the relationship between diabetes and risk of endometrial cancer in women. The major strength of this updated meta-analysis in compare to previous one is that more primary studies identified and included [8], therefore distinguished effects of diabetes on risk of developing endometrial cancer based on adjustments to BMI/weight presented with larger sample size (larger effect size).

Limitations

Included primary studies did not mention the duration of diabetes and type of treatment (oral anti hyperglycemic agents and/or insulin). Furthermore, identifying women with diabetes in the primary studies was almost based on their self-reports. Since the primary studies did not consider type of diabetes therefore it was not possible to estimate the possible risk separately in in type 1 and type 2 diabetes.

Conclusions

Diabetes seems to increases the risk of endometrial cancer in women, and this finding can be useful in developing endometrial cancer prevention plans for women having diabetes.

Acknowledgements

Not applicable.
Not applicable.
Not applicable.

Competing interests

The authors declare that they have no competing interests.
Open AccessThis article is distributed under the terms of the Creative Commons Attribution 4.0 International License (http://​creativecommons.​org/​licenses/​by/​4.​0/​), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver (http://​creativecommons.​org/​publicdomain/​zero/​1.​0/​) applies to the data made available in this article, unless otherwise stated.

Publisher’s Note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.
Literatur
1.
Zurück zum Zitat Lortet-Tieulent J, et al. International patterns and trends in endometrial cancer incidence, 1978–2013. J Natl Cancer Inst. 2017;110(4):354–61.CrossRef Lortet-Tieulent J, et al. International patterns and trends in endometrial cancer incidence, 1978–2013. J Natl Cancer Inst. 2017;110(4):354–61.CrossRef
2.
Zurück zum Zitat Stroup DF, et al. Meta-analysis of observational studies in epidemiology: a proposal for reporting. Jama. 2000;283(15):2008–12.CrossRef Stroup DF, et al. Meta-analysis of observational studies in epidemiology: a proposal for reporting. Jama. 2000;283(15):2008–12.CrossRef
3.
Zurück zum Zitat Parkin DM, Pisani P, Ferlay J. Global cancer statistics. CA Cancer J Clin. 1999;49(1):33–64.CrossRef Parkin DM, Pisani P, Ferlay J. Global cancer statistics. CA Cancer J Clin. 1999;49(1):33–64.CrossRef
4.
Zurück zum Zitat Luo J, et al. Association between diabetes, diabetes treatment and risk of developing endometrial cancer. Br J Cancer. 2014;111(7):1432.CrossRef Luo J, et al. Association between diabetes, diabetes treatment and risk of developing endometrial cancer. Br J Cancer. 2014;111(7):1432.CrossRef
5.
Zurück zum Zitat Anderson KE, et al. Diabetes and endometrial cancer in the Iowa women’s health study. Cancer Epidemiol Biomarkers Prev. 2001;10(6):611–6.PubMed Anderson KE, et al. Diabetes and endometrial cancer in the Iowa women’s health study. Cancer Epidemiol Biomarkers Prev. 2001;10(6):611–6.PubMed
6.
Zurück zum Zitat Lindemann K, et al. Body mass, diabetes and smoking, and endometrial cancer risk: a follow-up study. Br J Cancer. 2008;98(9):1582.CrossRef Lindemann K, et al. Body mass, diabetes and smoking, and endometrial cancer risk: a follow-up study. Br J Cancer. 2008;98(9):1582.CrossRef
7.
Zurück zum Zitat Ali A. Risk factors for endometrial cancer. Ceska Gynekol. 2013;78(5):448–59.PubMed Ali A. Risk factors for endometrial cancer. Ceska Gynekol. 2013;78(5):448–59.PubMed
8.
Zurück zum Zitat Friberg E, et al. Diabetes mellitus and risk of endometrial cancer: a meta-analysis. Diabetologia. 2007;50(7):1365–74.CrossRef Friberg E, et al. Diabetes mellitus and risk of endometrial cancer: a meta-analysis. Diabetologia. 2007;50(7):1365–74.CrossRef
9.
Zurück zum Zitat Knottnerus A, Tugwell P. STROBE—a checklist to Strengthen the Reporting of Observational Studies in Epidemiology. 2008;61(4):323. Knottnerus A, Tugwell P. STROBE—a checklist to Strengthen the Reporting of Observational Studies in Epidemiology. 2008;61(4):323.
10.
Zurück zum Zitat Von Elm E, et al. The strengthening the reporting of observational studies in epidemiology (STROBE) statement: guidelines for reporting observational studies. PLoS Med. 2007;4(10):e296.CrossRef Von Elm E, et al. The strengthening the reporting of observational studies in epidemiology (STROBE) statement: guidelines for reporting observational studies. PLoS Med. 2007;4(10):e296.CrossRef
11.
Zurück zum Zitat Greenland S. Quantitative methods in the review of epidemiologic literature. Epidemiol Rev. 1987;9(1):1–30.CrossRef Greenland S. Quantitative methods in the review of epidemiologic literature. Epidemiol Rev. 1987;9(1):1–30.CrossRef
12.
Zurück zum Zitat DerSimonian R, Laird N. Meta-analysis in clinical trials. Control Clin Trials. 1986;7(3):177–88.CrossRef DerSimonian R, Laird N. Meta-analysis in clinical trials. Control Clin Trials. 1986;7(3):177–88.CrossRef
13.
Zurück zum Zitat Higgins J, Thompson SG. Quantifying heterogeneity in a meta-analysis. Stat Med. 2002;21(11):1539–58.CrossRef Higgins J, Thompson SG. Quantifying heterogeneity in a meta-analysis. Stat Med. 2002;21(11):1539–58.CrossRef
14.
Zurück zum Zitat Egger M, Smith GD, Minder C. Bias in meta-analysis detected by a simple, graphical test. Br Med J. 1998;316(7129):470–1. Egger M, Smith GD, Minder C. Bias in meta-analysis detected by a simple, graphical test. Br Med J. 1998;316(7129):470–1.
15.
Zurück zum Zitat Egger M, et al. Bias in meta-analysis detected by a simple, graphical test. Bmj. 1997;315(7109):629–34.CrossRef Egger M, et al. Bias in meta-analysis detected by a simple, graphical test. Bmj. 1997;315(7109):629–34.CrossRef
16.
Zurück zum Zitat AlHilli M, et al. The impact of diabetes and metformin on clinical outcomes is negligible in risk-adjusted endometrial cancer cohorts. Gynecol Oncol. 2015;137:156–7.CrossRef AlHilli M, et al. The impact of diabetes and metformin on clinical outcomes is negligible in risk-adjusted endometrial cancer cohorts. Gynecol Oncol. 2015;137:156–7.CrossRef
17.
Zurück zum Zitat Friberg E, Mantzoros CS, Wolk A. Diabetes and risk of endometrial cancer: a population-based prospective cohort study. Cancer Epidemiol Biomarkers Prev. 2007;16(2):276–80.CrossRef Friberg E, Mantzoros CS, Wolk A. Diabetes and risk of endometrial cancer: a population-based prospective cohort study. Cancer Epidemiol Biomarkers Prev. 2007;16(2):276–80.CrossRef
18.
Zurück zum Zitat Lambe M, et al. Impaired glucose metabolism and diabetes and the risk of breast, endometrial, and ovarian cancer. Cancer Causes Control. 2011;22(8):1163–71.CrossRef Lambe M, et al. Impaired glucose metabolism and diabetes and the risk of breast, endometrial, and ovarian cancer. Cancer Causes Control. 2011;22(8):1163–71.CrossRef
19.
Zurück zum Zitat Coughlin SS, et al. Diabetes mellitus as a predictor of cancer mortality in a large cohort of US adults. Am J Epidemiol. 2004;159(12):1160–7.CrossRef Coughlin SS, et al. Diabetes mellitus as a predictor of cancer mortality in a large cohort of US adults. Am J Epidemiol. 2004;159(12):1160–7.CrossRef
20.
Zurück zum Zitat Folsom AR, et al. Diabetes as a risk factor for death following endometrial cancer. Gynecol Oncol. 2004;94(3):740–5.CrossRef Folsom AR, et al. Diabetes as a risk factor for death following endometrial cancer. Gynecol Oncol. 2004;94(3):740–5.CrossRef
21.
Zurück zum Zitat Terry P, et al. Lifestyle and endometrial cancer risk: a cohort study from the Swedish twin registry. Int J Cancer. 1999;82(1):38–42.CrossRef Terry P, et al. Lifestyle and endometrial cancer risk: a cohort study from the Swedish twin registry. Int J Cancer. 1999;82(1):38–42.CrossRef
22.
Zurück zum Zitat Brinton LA, et al. Reproductive, menstrual, and medical risk factors for endometrial cancer: results from a case-control study. Am J Obstet Gynecol. 1992;167(5):1317–25.CrossRef Brinton LA, et al. Reproductive, menstrual, and medical risk factors for endometrial cancer: results from a case-control study. Am J Obstet Gynecol. 1992;167(5):1317–25.CrossRef
23.
Zurück zum Zitat Friedenreich CM, et al. Case–control study of the metabolic syndrome and metabolic risk factors for endometrial cancer. Cancer Epidemiol Biomarkers Prev. 2011;20(11):2384–95.CrossRef Friedenreich CM, et al. Case–control study of the metabolic syndrome and metabolic risk factors for endometrial cancer. Cancer Epidemiol Biomarkers Prev. 2011;20(11):2384–95.CrossRef
24.
Zurück zum Zitat Inoue M, et al. A case-control study on risk factors for uterine endometrial Cancer in Japan. Cancer Sci. 1994;85(4):346–50. Inoue M, et al. A case-control study on risk factors for uterine endometrial Cancer in Japan. Cancer Sci. 1994;85(4):346–50.
25.
Zurück zum Zitat Lucenteforte E, et al. Diabetes and endometrial cancer: effect modification by body weight, physical activity and hypertension. Br J Cancer. 2007;97(7):995.CrossRef Lucenteforte E, et al. Diabetes and endometrial cancer: effect modification by body weight, physical activity and hypertension. Br J Cancer. 2007;97(7):995.CrossRef
26.
Zurück zum Zitat Parazzini F, et al. Diabetes and endometrial cancer: an Italian case-control study. Int J Cancer. 1999;81(4):539–42.CrossRef Parazzini F, et al. Diabetes and endometrial cancer: an Italian case-control study. Int J Cancer. 1999;81(4):539–42.CrossRef
27.
Zurück zum Zitat Rubin GL, et al. Estrogen replacement therapy and the risk of endometrial cancer: remaining controversies. Am J Obstet Gynecol. 1990;162(1):148–54.CrossRef Rubin GL, et al. Estrogen replacement therapy and the risk of endometrial cancer: remaining controversies. Am J Obstet Gynecol. 1990;162(1):148–54.CrossRef
28.
Zurück zum Zitat Salazar-Martínez E, et al. Case–control study of diabetes, obesity, physical activity and risk of endometrial cancer among Mexican women. Cancer Causes Control. 2000;11(8):707–11.CrossRef Salazar-Martínez E, et al. Case–control study of diabetes, obesity, physical activity and risk of endometrial cancer among Mexican women. Cancer Causes Control. 2000;11(8):707–11.CrossRef
29.
Zurück zum Zitat Saltzman BS, et al. Diabetes and endometrial cancer: an evaluation of the modifying effects of other known risk factors. 2007;167(5):607–14. Saltzman BS, et al. Diabetes and endometrial cancer: an evaluation of the modifying effects of other known risk factors. 2007;167(5):607–14.
30.
Zurück zum Zitat Shoff SM, Newcomb PA. Diabetes, body size, and risk of endometrial cancer. Am J Epidemiol. 1998;148(3):234–40.CrossRef Shoff SM, Newcomb PA. Diabetes, body size, and risk of endometrial cancer. Am J Epidemiol. 1998;148(3):234–40.CrossRef
31.
Zurück zum Zitat Soliman PT, et al. Association between adiponectin, insulin resistance, and endometrial cancer. Cancer. 2006;106(11):2376–81.CrossRef Soliman PT, et al. Association between adiponectin, insulin resistance, and endometrial cancer. Cancer. 2006;106(11):2376–81.CrossRef
32.
Zurück zum Zitat Wartko PD, et al. Association of endometrial hyperplasia and cancer with a history of gestational diabetes. Cancer Causes Control. 2017;28(8):819–28.CrossRef Wartko PD, et al. Association of endometrial hyperplasia and cancer with a history of gestational diabetes. Cancer Causes Control. 2017;28(8):819–28.CrossRef
33.
Zurück zum Zitat Weiderpass E, et al. Body size in different periods of life, diabetes mellitus, hypertension, and risk of postmenopausal endometrial cancer (Sweden). Cancer Causes Control. 2000;11(2):185–92.CrossRef Weiderpass E, et al. Body size in different periods of life, diabetes mellitus, hypertension, and risk of postmenopausal endometrial cancer (Sweden). Cancer Causes Control. 2000;11(2):185–92.CrossRef
34.
Zurück zum Zitat Weiss JM, et al. Risk factors for the incidence of endometrial cancer according to the aggressiveness of disease. Am J Epidemiol. 2006;164(1):56–62.CrossRef Weiss JM, et al. Risk factors for the incidence of endometrial cancer according to the aggressiveness of disease. Am J Epidemiol. 2006;164(1):56–62.CrossRef
35.
Zurück zum Zitat Tsilidis KK, et al. Type 2 diabetes and cancer: umbrella review of meta-analyses of observational studies. Bmj. 2015;350:g7607.CrossRef Tsilidis KK, et al. Type 2 diabetes and cancer: umbrella review of meta-analyses of observational studies. Bmj. 2015;350:g7607.CrossRef
36.
Zurück zum Zitat Austin MA, et al. The effect of response bias on the odds ratio. Am J Epidemiol. 1981;114(1):137–43.CrossRef Austin MA, et al. The effect of response bias on the odds ratio. Am J Epidemiol. 1981;114(1):137–43.CrossRef
37.
Zurück zum Zitat Heid I, et al. On the potential of measurement error to induce differential bias on odds ratio estimates: an example from radon epidemiology. Stat Med. 2002;21(21):3261–78.CrossRef Heid I, et al. On the potential of measurement error to induce differential bias on odds ratio estimates: an example from radon epidemiology. Stat Med. 2002;21(21):3261–78.CrossRef
38.
Zurück zum Zitat Nemes S, et al. Bias in odds ratios by logistic regression modelling and sample size. BMC Med Res Methodol. 2009;9(1):56.CrossRef Nemes S, et al. Bias in odds ratios by logistic regression modelling and sample size. BMC Med Res Methodol. 2009;9(1):56.CrossRef
39.
Zurück zum Zitat Clayton D, Hills M, Pickles A. Statistical models in epidemiology, vol. 161. Oxford: Oxford university press; 1993. Clayton D, Hills M, Pickles A. Statistical models in epidemiology, vol. 161. Oxford: Oxford university press; 1993.
40.
Zurück zum Zitat Schulz KF, Grimes DA. Case-control studies: research in reverse. Lancet. 2002;359(9304):431–4.CrossRef Schulz KF, Grimes DA. Case-control studies: research in reverse. Lancet. 2002;359(9304):431–4.CrossRef
41.
Zurück zum Zitat Wacholder S, et al. Selection of controls in case-control studies: II. Types of controls. Am J Epidemiol. 1992;135(9):1029–41.CrossRef Wacholder S, et al. Selection of controls in case-control studies: II. Types of controls. Am J Epidemiol. 1992;135(9):1029–41.CrossRef
42.
Zurück zum Zitat Arima R, et al. Cause-specific mortality in endometrioid endometrial cancer patients with type 2 diabetes using metformin or other types of antidiabetic medication. Gynecol Oncol. 2017;147(3):678–83.CrossRef Arima R, et al. Cause-specific mortality in endometrioid endometrial cancer patients with type 2 diabetes using metformin or other types of antidiabetic medication. Gynecol Oncol. 2017;147(3):678–83.CrossRef
43.
Zurück zum Zitat Arima R, et al. Antidiabetic medication, statins and the risk of endometrioid endometrial cancer in patients with type 2 diabetes. Gynecol Oncol. 2017;146(3):636–41.CrossRef Arima R, et al. Antidiabetic medication, statins and the risk of endometrioid endometrial cancer in patients with type 2 diabetes. Gynecol Oncol. 2017;146(3):636–41.CrossRef
44.
Zurück zum Zitat Park Y, Colditz GA. Diabetes and adiposity: a heavy load for cancer. Lancet Diabetes Endocrinol. 2018;6(2):82–3.CrossRef Park Y, Colditz GA. Diabetes and adiposity: a heavy load for cancer. Lancet Diabetes Endocrinol. 2018;6(2):82–3.CrossRef
45.
Zurück zum Zitat Nagamani M, Stuart CA. Specific binding and growth-promoting activity of insulin in endometrial cancer cells in culture. Am J Obstet Gynecol. 1998;179(1):6–12.CrossRef Nagamani M, Stuart CA. Specific binding and growth-promoting activity of insulin in endometrial cancer cells in culture. Am J Obstet Gynecol. 1998;179(1):6–12.CrossRef
46.
Zurück zum Zitat Murphy LJ. Growth factors and steroid hormone action in endometrial cancer. J Steroid Biochem Mol Biol. 1994;48(5–6):419–23.CrossRef Murphy LJ. Growth factors and steroid hormone action in endometrial cancer. J Steroid Biochem Mol Biol. 1994;48(5–6):419–23.CrossRef
47.
Zurück zum Zitat Corocleanu M. Hypothesis for endometrial carcinoma carcinogenesis. Preventive prospects. Clin Exp Obstet Gynecol. 1993;20(4):254–8.PubMed Corocleanu M. Hypothesis for endometrial carcinoma carcinogenesis. Preventive prospects. Clin Exp Obstet Gynecol. 1993;20(4):254–8.PubMed
48.
Zurück zum Zitat Thiet M-P, Osathanondh R, Yeh J. Localization and timing of appearance of insulin, insulin-like growth factor-I, and their receptors in the human fetal müllerian tract. Am J Obstet Gynecol. 1994;170(1):152–6.CrossRef Thiet M-P, Osathanondh R, Yeh J. Localization and timing of appearance of insulin, insulin-like growth factor-I, and their receptors in the human fetal müllerian tract. Am J Obstet Gynecol. 1994;170(1):152–6.CrossRef
49.
Zurück zum Zitat Ordener C, et al. Epidermal growth factor and insulin induce the proliferation of Guinea pig endometrial stromal cells in serum-free culture, whereas estradiol and progesterone do not. Biol Reprod. 1993;49(5):1032–44.CrossRef Ordener C, et al. Epidermal growth factor and insulin induce the proliferation of Guinea pig endometrial stromal cells in serum-free culture, whereas estradiol and progesterone do not. Biol Reprod. 1993;49(5):1032–44.CrossRef
50.
Zurück zum Zitat Friberg E, et al. Coffee drinking and risk of endometrial cancer—a population-based cohort study. Int J Cancer. 2009;125(10):2413–7.CrossRef Friberg E, et al. Coffee drinking and risk of endometrial cancer—a population-based cohort study. Int J Cancer. 2009;125(10):2413–7.CrossRef
Metadaten
Titel
The effect of diabetes on the risk of endometrial Cancer: an updated a systematic review and meta-analysis
verfasst von
Lotfolah Saed
Fatemeh Varse
Hamid Reza Baradaran
Yousef Moradi
Sorour Khateri
Emilie Friberg
Zaher Khazaei
Saeedeh Gharahjeh
Shahrzad Tehrani
Amir-Babak Sioofy-Khojine
Zahra Najmi
Publikationsdatum
01.12.2019
Verlag
BioMed Central
Erschienen in
BMC Cancer / Ausgabe 1/2019
Elektronische ISSN: 1471-2407
DOI
https://doi.org/10.1186/s12885-019-5748-4

Weitere Artikel der Ausgabe 1/2019

BMC Cancer 1/2019 Zur Ausgabe

Update Onkologie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.